Inhibition of HMGB1 Overcomes Resistance to Radiation and Chemotherapy in Nasopharyngeal Carcinoma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Jun 12

PMID 32523355

Citations 16

Authors

Xuewei Zhu

Jianan Cong

Zhang Lin

Jing Sun

Ben Yang

Aipeng Li

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to investigate the effect of high mobility group protein B1 (HMGB1) on chemoresistance and radioresistance in nasopharyngeal carcinoma (NPC).

Materials And Methods: HMGB1-knockout HK1 cell lines were generated using clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system. Western blotting was used to evaluate the protein expression level of HMGB1. DNA repair efficiency of non-homologous end joining (NHEJ) and homologous recombination (HR) was monitored through NHEJ and HR reporter assay. Cellular protein-protein interaction between HMGB1 and NHEJ apparatus was determined by immunoprecipitation. Direct protein-protein interaction was examined by affinity capture assay with purified protein. Protein-DNA binding was evaluated by chromatin fractionation assay. Cell viability assay was employed to measure cell sensitivity to ionizing radiation (IR) or cisplatin.

Results: HMGB1-knockout NPC cells showed significant decrease in NHEJ efficiency. HMGB1 immunoprecipitated NHEJ key factors in NPC cells and promoted DNA-binding activity of Ku70. Mutational analysis revealed that serine 155 of Ku70 was required for its direct interaction with HMGB1. HMGB1 was highly expressed in radio- and chemoresistant NPC cells. Deficiency of HMGB1 sensitized wild-type (WT) and resistant NPC cells to IR and cisplatin. Glycyrrhizin, which is HMGB1 inhibitor, impaired DNA binding of HMGB1 and exhibited excellent synergy with IR and cisplatin.

Conclusion: HMGB1 promotes NHEJ via interaction with Ku70 resulting in resistance to IR and cisplatin. Inhibition of HMGB1 by glycyrrhizin is a potential therapeutic regimen to treat cisplatin and IR resistant NPC patients.

Citing Articles

Heterogeneous nuclear ribonucleoprotein K is a potential target for enhancing the chemosensitivity of nasopharyngeal carcinoma.

Yang M, Ke Z, Wang D Open Life Sci. 2024; 19(1):20220975.

PMID: 39479349 PMC: 11524390. DOI: 10.1515/biol-2022-0975.

Glycyrrhizin ameliorates colorectal cancer progression by regulating NHEJ pathway through inhibiting HMGB1-induced DNA damage response.

Han Y, Sheng W, Liu X, Liu H, Jia X, Li H Sci Rep. 2024; 14(1):24948.

PMID: 39438689 PMC: 11496679. DOI: 10.1038/s41598-024-76155-w.

Methylation of is a synthetic lethal marker for ATR/CHK1 inhibitors in pancreatic cancer.

Liu F, Gao A, Zhang M, Li Y, Zhang F, Herman J J Transl Int Med. 2024; 12(3):274-287.

PMID: 39081276 PMC: 11284899. DOI: 10.2478/jtim-2023-0128.

The role of lncRNA NEAT1 in human cancer chemoresistance.

Long F, Li X, Pan J, Ye H, Di C, Huang Y Cancer Cell Int. 2024; 24(1):236.

PMID: 38970092 PMC: 11227196. DOI: 10.1186/s12935-024-03426-x.

Multiple functions of HMGB1 in cancer.

Lv G, Yang M, Gai K, Jia Q, Wang Z, Wang B Front Oncol. 2024; 14:1384109.

PMID: 38725632 PMC: 11079206. DOI: 10.3389/fonc.2024.1384109.

References

Fell V, Schild-Poulter C . Ku regulates signaling to DNA damage response pathways through the Ku70 von Willebrand A domain. Mol Cell Biol. 2011; 32(1):76-87. PMC: 3255697. DOI: 10.1128/MCB.05661-11. View

Paiar F, Di Cataldo V, Zei G, Monteleone Pasquetti E, Cecchini S, Meattini I . Role of chemotherapy in nasopharyngeal carcinoma. Oncol Rev. 2015; 6(1):e1. PMC: 4419643. DOI: 10.4081/oncol.2012.e1. View

Valerie K, Povirk L . Regulation and mechanisms of mammalian double-strand break repair. Oncogene. 2003; 22(37):5792-812. DOI: 10.1038/sj.onc.1206679. View

Lange S, Mitchell D, Vasquez K . High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc Natl Acad Sci U S A. 2008; 105(30):10320-5. PMC: 2492475. DOI: 10.1073/pnas.0803181105. View

FORSBY N, Klein G, Henle W . Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int J Cancer. 1977; 20(4):486-94. DOI: 10.1002/ijc.2910200403. View

Ward M, Pan W, Cheng Y, Li F, Brinton L, Chen C . Dietary exposure to nitrite and nitrosamines and risk of nasopharyngeal carcinoma in Taiwan. Int J Cancer. 2000; 86(5):603-9. DOI: 10.1002/(sici)1097-0215(20000601)86:5<603::aid-ijc1>3.0.co;2-h. View

Yamaguchi H, Kidachi Y, Kamiie K, Noshita T, Umetsu H . Structural insight into the ligand-receptor interaction between glycyrrhetinic acid (GA) and the high-mobility group protein B1 (HMGB1)-DNA complex. Bioinformation. 2013; 8(23):1147-53. PMC: 3530883. DOI: 10.6026/97320630081147. View

Wang J, Shi M, Hsia Y, Luo S, Zhao L, Xu M . Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study. Radiat Oncol. 2012; 7:2. PMC: 3269351. DOI: 10.1186/1748-717X-7-2. View

Andersson U, Erlandsson-Harris H, Yang H, Tracey K . HMGB1 as a DNA-binding cytokine. J Leukoc Biol. 2002; 72(6):1084-91. View

10.

Chung S, Wu C, Lin H, Hung S . Association between allergic rhinitis and nasopharyngeal carcinoma: a population-based study. Laryngoscope. 2013; 124(8):1744-9. DOI: 10.1002/lary.24532. View

11.

Chen X, Li W, Wu X, Zhang H, Chen L, Zhang P . Dicer regulates non-homologous end joining and is associated with chemosensitivity in colon cancer patients. Carcinogenesis. 2017; 38(9):873-882. DOI: 10.1093/carcin/bgx059. View

12.

Ma Y, Lu H, Tippin B, Goodman M, Shimazaki N, Koiwai O . A biochemically defined system for mammalian nonhomologous DNA end joining. Mol Cell. 2004; 16(5):701-13. DOI: 10.1016/j.molcel.2004.11.017. View

13.

Lee A, Lin J, Ng W . Current management of nasopharyngeal cancer. Semin Radiat Oncol. 2012; 22(3):233-44. DOI: 10.1016/j.semradonc.2012.03.008. View

14.

Volp K, Brezniceanu M, Bosser S, Brabletz T, Kirchner T, Gottel D . Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 2005; 55(2):234-42. PMC: 1856519. DOI: 10.1136/gut.2004.062729. View

15.

Czura C, Wang H, Tracey K . Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res. 2001; 7(4):315-21. DOI: 10.1177/09680519010070041401. View

16.

Schroter H, Bode J . The binding sites for large and small high-mobility-group (HMG) proteins. Studies on HMG-nucleosome interactions in vitro. Eur J Biochem. 1982; 127(2):429-36. DOI: 10.1111/j.1432-1033.1982.tb06890.x. View

17.

Lieber M, Ma Y, Pannicke U, Schwarz K . Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol. 2003; 4(9):712-20. DOI: 10.1038/nrm1202. View

18.

Kawahara N, Tanaka T, Yokomizo A, Nanri H, Ono M, Wada M . Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res. 1996; 56(23):5330-3. View

19.

Burma S, Chen B, Chen D . Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (Amst). 2006; 5(9-10):1042-8. DOI: 10.1016/j.dnarep.2006.05.026. View

20.

Li Y, Wang X, Pan Y, Lee D, Chowdhury D, Kimmelman A . Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response. PLoS One. 2012; 7(6):e39588. PMC: 3377637. DOI: 10.1371/journal.pone.0039588. View